相关实验视频

Updated: Jul 13, 2025

Bronchoalveolar Lavage Exosomes in Lipopolysaccharide-induced Septic Lung Injury

Bronchoalveolar Lavage Exosomes in Lipopolysaccharide-induced Septic Lung Injury

Published on: May 21, 2018

用于治疗肺炎的PD-L1-表达细胞外囊泡

Yi Wu^1,2, Heng Wang¹, Anning Song¹

¹Institute of Functional Nano & Soft Materials (FUNSOM) Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Soochow University, Suzhou, Jiangsu 215123, P. R. China.

ACS biomaterials science & engineering

|October 16, 2023

概括

与PD-L1进行工程的介质干细胞衍生的细胞外囊泡 (MSC-EVs) 显示出治疗肺炎的前景. 通过MSC-EVs-PD-L1的内输送,通过PD-1/PD-L1通路有效抑制了肺炎.

科学领域:

免疫学免疫学免疫学
再生医学是一种再生医学.
肺部医学肺部医学

背景情况:

由于高死亡率和有限的治疗选择,急性呼吸困扰综合征 (ARDS) 呈现出严重的未满足的医疗需求.
肺炎是ARDS的常见原因,通常涉及严重的肺炎和免疫失调.
目前用于重症肺炎和ARDS的治疗方法缺乏向疗效,并且可能产生全身副作用.

研究的目的:

开发一种新的无细胞肺炎治疗策略,使用工程外细胞囊泡.
在脂多糖 (LPS) 诱导的肺炎模型中,研究介质干细胞 (MSC) 衍生的细胞外囊泡 (EVs) 的高编程死亡配体1 (PD-L1) 表达 (MSC-EVs-PD-L1) 的疗效.
为了阐明由MSC-EVs-PD-L1通过PD-1/PD-L1信号通路调解的潜在的免疫抑制机制.

主要方法:

通过基因工程或特定的隔离技术开发MSC-EVs-PD-L1.
建立LPS诱导的肺炎的小鼠模型,以模仿急性肺损伤.
用MSC-EVs-PD-L1进行内注射,以评估治疗效果和药物在肺部的分布.
在炎症肺组织中分析PD-1表达和评估PD-1/PD-L1信号通路的作用.

主要成果:

证明了MSC-EV的成功工程,以表达高水平的PD-L1.
在LPS挑战后,在小鼠肺部的炎症区域观察到PD-1表达的显著上调.
证实MSC-EVs-PD-L1通过启动PD-1/PD-L1通路产生强大的免疫抑制作用.
与系统性输送相比,当通过内给药时,显示出优异的治疗疗效和MSC-EVs-PD-L1的向肺积累.

结论:

MSC-EVs-PD-L1代表了一种有前途的无细胞免疫治疗肺炎的方法.
内输送通过将EVs集中在受影响的肺组织中来提高治疗效果.
这种工程 EV 平台具有在各种肺炎疾病的免疫治疗中广泛应用的潜力.

关键词:

急性呼吸困扰综合征是什么细胞外囊泡中的细胞外囊泡.免疫疗法免疫疗法脂多糖诱发的肺炎.介质细胞干细胞介质细胞干细胞

更多相关视频

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Isolation of Extracellular Vesicles from Murine Bronchoalveolar Lavage Fluid Using an Ultrafiltration Centrifugation Technique

Isolation of Extracellular Vesicles from Murine Bronchoalveolar Lavage Fluid Using an Ultrafiltration Centrifugation Technique

Published on: November 9, 2018

相关概念视频

Pneumonia II: Pathophysiology

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:

Pneumonia IV: Management

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...

Pneumonia V: Nursing management and Prevention

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....